The hope that a simple, affordable, and safe homocysteine-lowering intervention with folic acid and vitamin B12 would improve outcomes for patients with established cardiovascular or renal disease has been crushed by the null results from large B-vitamin treatment trials completed to date.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Joseph, J., Handy, D. E. & Loscalzo, J. Quo vadis: whither homocysteine research? Cardiovasc. Toxicol. 9, 53–63 (2009).
Humphrey, L. L., Fu, R., Rogers, K., Freeman, M. & Helfand, M. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin. Proc. 83, 1203–1212 (2008).
Armitage, J. M. et al. for the SEARCH Collaborative Group. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA 303, 2486–2494 (2010).
Clarke, R. et al. for the B-Vitamin Treatment Trialists' Collaboration. Effects of homocysteine-lowering with B-vitamins on cardiovascular disease, cancer and cause-specific mortality: meta-analysis of 8 randomized trials involving 37,485 individuals (in press).
Cole, B. F. et al. for the Polyp Prevention Study Group. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 297, 2351–2359 (2007).
Ebbing, M. et al. Cancer incidence and mortality after treatment with folic acid and vitamin B12 . JAMA 302, 2119–2126 (2009).
Hustad, S. et al. The methylenetetrahydrofolate reductase 677C T polymorphism as a modulator of a B vitamin network with major effects on homocysteine metabolism. Am. J. Hum. Genet. 80, 846–855 (2007).
Lichtenstein, A. H. & Russell, R. M. Essential nutrients: food or supplements? Where should the emphasis be? JAMA 294, 351–358 (2005).
Refsum, H. et al. The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. J. Nutr. 136, 1731S–1740S (2006).
Ebbing, M. et al. Combined analyses and extended follow-up of two randomized controlled homocysteine-lowering B-vitamin trials. J. Intern. Med. doi: 10.1111/j.1365–27962010.02259.x.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P. M. Ueland is a member of the steering board of the nonprofit Foundation to Promote Research into Functional Vitamin B12 Deficiency, and Bevital AS, a company owned by the foundation. M. Ebbing declares no competing interests.
Rights and permissions
About this article
Cite this article
Ebbing, M., Ueland, P. B vitamins and CVD—failure to find a simple solution. Nat Rev Cardiol 7, 608–609 (2010). https://doi.org/10.1038/nrcardio.2010.138
Published:
Issue date:
DOI: https://doi.org/10.1038/nrcardio.2010.138
This article is cited by
-
Excess nicotinamide inhibits methylation-mediated degradation of catecholamines in normotensives and hypertensives
Hypertension Research (2012)
-
Dietary methyl-consuming compounds and metabolic syndrome
Hypertension Research (2011)